Androgen activates β-catenin signaling in bladder cancer cells

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 293-304

  Li, Yi ^a,b   Zheng, Yichun ^a,b   Izumi, Koji ^a   Ishiguro, Hitoshi ^a   Ye, Bo ^a   Li, Faqian ^a   Miyamoto, Hiroshi ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Androgen receptor; Antiandrogen; Bladder cancer; TCF LEF; Wnt catenin

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; HYDROXYFLUTAMIDE; T CELL FACTOR PROTEIN;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; UPREGULATION; WNT SIGNALING PATHWAY;

ANDROGEN RECEPTOR; ANTIANDROGEN; BLADDER CANCER; TCF/LEF; WNT/Β-CATENIN;

AGED; AGED, 80 AND OVER; ANDROGENS; BETA CATENIN; CARCINOMA; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; METRIBOLONE; MIDDLE AGED; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84879474174     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0328     Document Type: Article

References (51)

1. Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R & Birchmeier W 1996 Functional interaction of β-catenin with the transcription factor LEF-1. Nature 382 638-642. (doi:10.1038/382638a0)
2. Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ & Tindall TJ 2009 Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocrine-Related Cancer 16 123-137. (doi:10.1677/ERC-08-0124)
3. Brabletz T, Herrmann K, Jung A, Faller G & Kirchner T 2000 Expression of nuclear β-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. American Journal of Pathology 156 865-870. (doi:10.1016/S0002-9440(10)64955-3)
4. Bui TD, O'Brien T, Crew J, Cranston D & Harris AL 1998 High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer. British Journal of Cancer 77 319-324. (doi:10.1038/bjc.1998.49)
5. Chesire DR & Isaacs WB 2003 β-catenin signaling in prostate cancer: an early perspective. Endocrine-Related Cancer 10 537-560. (doi:10.1677/erc.0.0100537)
6. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
7. Garcia del Muro X, Torregrosa A, Muñoz J, Castellsagué X, Condom E, Vigués F, Vigués F, Arance A, Fabra A & Germà JR 2000 Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer. European Journal of Cancer 36 357-362. (doi:10.1016/S0959-8049 (99)00262-2)
8. Gavert N & Ben-Ze'ev A 2007 β-catenin signaling in biological control and cancer. Journal of Cellular Biochemistry 102 820-828. (doi:10.1002/jcb. 21505)
9. Heinlein CA & Chang C 2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276-308. (doi:10.1210/er.2002-0032)
10. Hirata H, Hinoda Y, Ueno K, Shahryari V, Tabatabai ZL & Dahiya R 2012 MicroRNA-1826 targets VEGFC, β-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 33 41-48. (doi:10.1093/carcin/bgr239)
11. Hsieh S-Y, Hsieh P-S, Chiu C-T & Chen W.-Y. 2004 Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 23 9183-9189.
12. Hu X, Ruan Y, Cheng F, Yu W, Zhang X & Larré S 2011 p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. International Journal of Urology 18 630-637.
13. Izumi K, Zheng Y, Li Y, Zaengle J & Miyamoto H 2012 Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. International Journal of Oncology 241 1587-1592.
14. Izumi K, Zheng Y, Hsu J-W, Chang C & Miyamoto H 2013 Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Molecular Carcinogenesis 52 94-102. (doi:10.1002/mc.21833)
15. Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM & Reeder JE 2008 Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urology 8 7. (doi:10.1186/1471-2490-8-7)
16. Kastritis E, Murray S, Kyriakou F, Horti M, Tamvakis N, Kavantzas N, Patsouris ES, Noni A, Legaki S, Dimopoulos MA et al. 2009 Somatic mutations of adenomatous polyposis coli gene and nuclear β-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. International Journal of Cancer 124 103-108. (doi:10.1002/ijc.23917)
17. Lako M, Strachan T, Bullen P, Wilson DI, Robson SC & Lindsay S 1998 Isolation, characterisation and embryonic expression of WNT11, a gene which maps to 11q13.5 and has possible roles in the development of skeleton, kidney and lung. Gene 219 101-110. (doi:10.1016/S0378-1119(98)00393-X)
18. Li Y, Izumi K & Miyamoto H 2012 The role of the androgen receptor in the development and progression of bladder cancer. Japanese Journal of Clinical Oncology 42 569-577. (doi:10.1093/jjco/hys072)
19. Lipponen PK 1995 Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. Journal of Pathology 175 203-210. (doi:10.1002/path.1711750208)
20. Lustig B & Behrens J 2003 The Wnt signaling pathway and its role in tumor development. Journal of Cancer Research and Clinical Oncology 129 199-221.
21. Miller JR & Moon RT 1996 Signal transduction through β-catenin and specification of cell fate during embryogenesis. Genes and Development 10 2527-2539. (doi:10.1101/gad.10.20.2527)
22. Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang Y-J, Hu Y-C, Tsai M-Y et al. 2007 Promotion of bladder cancer development and progression by androgen receptor signals. Journal of the National Cancer Institute 99 558-568. (doi:10.1093/jnci/djk113)
23. Miyamoto H, Zheng Y & Izumi K 2012 Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Current Cancer Drug Targets 12 14-22. (doi:10.2174/156800912798888965)
24. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET & Namiki M 2004 The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Research 64 765-771. (doi:10.1158/0008-5472.CAN-03- 0130)
25. Morin PJ 1999 β-catenin signaling and cancer. Bio Essays 21 1021-1030. (doi:10.1002/(SICI)1521-1878(199912)22:1!1021::AID-BIES6O3.0. CO;2-P)
26. Mulholland DJ, Cheng H, Reid K, Rennie PS & Nelson CC 2002 The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli. Journal of Biological Chemistry 277 17933-17943. (doi:10.1074/jbc.M200135200)
27. Mulholland DJ, Read JT, Rennie PS, Cox ME & Nelson CC 2003 Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a mean for inhibition of the Tcf signaling axis. Oncogene 22 5602-5613. (doi:10.1038/sj.onc.1206802)
28. Nakopoulou L, Zervas A, Gakiopoulou-Givalou H, Constantinides C, Doumanis G, Davaris P & Dimopoulos C 2000 Prognostic value of E-cadherin, β-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Research 20 4571-4578.
29. Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM & Wierman ME 2002 Liganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. Journal of Biological Chemistry 277 20702-20710. (doi:10.1074/jbc.M200545200)
30. Polakis P 1999 The oncogenic activation of β-catenin. Current Opinion in Genetics & Development 9 15-21. (doi:10.1016/S0959-437X(99)80003- 3)
31. Polakis P 2000 Wnt signaling and cancer. Genes and Development 14 1837-1851.
32. Schmitz-Drager BJ, Schulz WA, Jürgens B, Gerharz CD, van Roeyen CR, Bültel H, Bültel H, Ebert T & Ackermann R 1997 c-myc in bladder cancer. Clinical findings and analysis of mechanism. Urological Research 25 (Suppl 1) S45-S49. (doi:10.1007/BF00942047)
33. Sedelaar JPM & Isaacs JT 2009 Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate 69 1724-1729. (doi:10.1002/pros.21028)
34. Shair KHY, Schnegg CI & Raab-Traub N 2009 Epstein-Barr virus latent membrane protein-1 effects on junctional plakoglobin and induction of a cadherin switch. Cancer Research 69 5734-5742. (doi:10.1158/0008-5472.CAN-09-0468)
35. Shiina H, Igawa M, Shigeno K, Terashima M, Deguchi M, Yamanaka M, Ribeiro-Filho L, Kane CJ & Dahiya R 2002 β-catenin mutations correlate with over expression of c-myc and cyclin D1 genes in bladder cancer. Journal of Urology 168 2220-2226. (doi:10.1016/S0022-5347 (05)64359-5)
36. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF & Bhasin S 2006 Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with β-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147 141-154. (doi:10.1210/en.2004-1649)
37. Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, Krishnan V, Sinha SK, Rajavashisth TB & Jasuja R 2009 Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/β- catenin and follistatin/transforming growth factor-β signaling pathways. Endocrinology 150 1259-1268. (doi:10.1210/en.2008-0858)
38. Stoehr R, Krieg RC, Knuechel R, Hofstaedter F, Pilarsky C, Zaak D, Schmitt R & Hartmann A 2002 No evidence for involvement of β-catenin and APC in urothelial carcinomas. International Journal of Oncology 20 905-911.
39. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G et al. 2004 Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Laboratory Investigation 84 465-478. (doi:10.1038/labinvest. 3700068)
40. Tan X, Apte U, Micsenyi A, Kotsagrelos E, Luo J-H, Ranganathan S, Monga DK, Bell A, Michalopoulos GK & Monga SPS 2005 Epidermal growth factor receptor: a novel target of the Wnt/β-catenin pathway in liver. Gastroenterology 129 285-302. (doi:10.1053/j.gastro.2005.04.013)
41. Tang Y, Simoneau AR, Liao W-X, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA et al. 2009 WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Molecular Cancer Therapeutics 8 458-468. (doi:10.1158/1535-7163.MCT-08-0885)
42. Tian X, Li J, Ma Z-M, Zhao C, Wan D-F & Wen Y-M 2009 Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1. Journal of Experimental & Clinical Cancer Research 28 58. (doi:10.1186/1756-9966-28-58)
43. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li L-C, Ribeiro-Filho LA, Terashima M et al. 2006 Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clinical Cancer Research 12 383-391. (doi:10.1158/1078-0432. CCR-05-1344)
44. Vlad A, Röhrs S, Klein-Hitpass L & Müller O 2008 The first five years of the Wnt targetome. Cellular Signaling 20 795-802. (doi:10.1016/j.cellsig. 2007.10.031)
45. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA & Visakorpi T 2009 Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Research 69 8141-8149. (doi:10.1158/0008-5472.CAN-09-0919)
46. Wang G, Wang J & Sadar MD 2008 Crosstalk between the androgen receptor and β-catenin in castrate-resistant prostate cancer. Cancer Research 68 9918-9927. (doi:10.1158/0008-5472.CAN-08-1718)
47. Wu J-T, Han B-M, Yu S-Q, Wang H-P & Xia S-J 2010 Androgen receptor is a potential therapeutic target for bladder cancer. Urology 75 820-827. (doi:10.1016/j.urology.2009.10.041)
48. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B & Sun Z 2002 Linking β-catenin to androgen-signaling pathway. Journal of Biological Chemistry 277 11336-11344. (doi:10.1074/jbc.M111962200)
49. Yumoto F, Nguyen P, Sablin EP, Baxter JD, Webb P & Fletterick RJ 2011 Structural basis of coactivation of liver receptor homolog-1 by β-catenin. PNAS 109 143-148. (doi:10.1073/pnas.1117036108)
50. Zheng Y, Izumi K, Yao JL & Miyamoto H 2011 Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocrine-Related Cancer 18 451-464. (doi:10.1530/ERC-11-0010)
51. Zhu X, Kanai Y, Saito A, Kondo Y & Hirohashi S 2000 Aberrant expression of β-catenin and mutation of exon 3 of the β-catenin gene in renal and urothelial carcinomas. Pathology International 50 945-952. (doi:10.1046/j.1440-1827.2000.01139.x)